|
1
|
Jemal A, Thun MJ, Ries LA, et al: Annual
report to the nation on the status of cancer, 1975–2005, featuring
trends in lung cancer, tobacco use, and tobacco control. J Natl
Cancer Inst. 100:1672–1694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
|
|
3
|
Salama JK and Vokes EE: New radiotherapy
and chemoradiotherapy approaches for non-small-cell lung cancer. J
Clin Oncol. 31:1029–1038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu Y, Zhang Y and Ma S: EGFR inhibitors
with concurrent thoracic radiation therapy for locally advanced
non-small cell lung cancer. Lung Cancer. 73:249–255. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. New Engl J Med. 346:92–98. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smit EF, van Meerbeeck JP, Lianes P, et
al: Three-arm randomized study of two cisplatin-based regimens and
paclitaxel plus gemcitabine in advanced non-small-cell lung cancer:
a phase III trial of the European Organization for Research and
Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol.
21:3909–3917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. New Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar
|
|
10
|
Brandao GD, Brega EF and Spatz A: The role
of molecular pathology in non-small-cell lung carcinoma-now and in
the future. Curr Oncol. 19(Suppl 1): S24–S32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar
|
|
12
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
New Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
14
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. New Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. New Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mok TS, Wu YL, Yu CJ, et al: Randomized,
placebo-controlled, phase II study of sequential erlotinib and
chemotherapy as first-line treatment for advanced non-small-cell
lung cancer. J Clin Oncol. 27:5080–5087. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herbst RS, Prager D, Hermann R, et al:
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774)
combined with carboplatin and paclitaxel chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol. 23:5892–5899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davies AM, Ho C, Lara PN Jr, Mack P,
Gumerlock PH and Gandara DR: Pharmacodynamic separation of
epidermal growth factor receptor tyrosine kinase inhibitors and
chemotherapy in non-small-cell lung cancer. Clin Lung Cancer.
7:385–388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gandara DR and Gumerlock PH: Epidermal
growth factor receptor tyrosine kinase inhibitors plus
chemotherapy: case closed or is the jury still out? J Clin Oncol.
23:5856–5858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Normanno N: Gefitinib and cisplatin-based
chemotherapy in non-small-cell lung cancer: simply a bad
combination? J Clin Oncol. 23:928–930. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baselga J: Combining the anti-EGFR agent
gefitinib with chemotherapy in non-small-cell lung cancer: how do
we go from INTACT to impact? J Clin Oncol. 22:759–761. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Milano G, Spano JP and Leyland-Jones B:
EGFR-targeting drugs in combination with cytotoxic agents: from
bench to bedside, a contrasted reality. Br J Cancer. 99:1–5. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao Q, Shentu J, Xu N, et al: Phase I
study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine
kinase inhibitor, in patients with advanced NSCLC and other solid
tumors. Lung Cancer. 73:195–202. 2011. View Article : Google Scholar
|
|
26
|
Shi Y, Zhang L, Liu X, et al: Icotinib
versus gefitinib in previously treated advanced non-small-cell lung
cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority
trial. Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu JM, Azzariti A, Colucci G and Paradiso
A: The effect of gefitinib (Iressa, ZD1839) in combination with
oxaliplatin is schedule-dependent in colon cancer cell lines.
Cancer Chemother Pharmacol. 52:442–448. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng H, An SJ, Dong S, et al: Molecular
mechanism of the schedule-dependent synergistic interaction in
EGFR-mutant non-small cell lung cancer cell lines treated with
paclitaxel and gefitinib. J Hematol Oncol. 4:52011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng H, An SJ, Zhang XC, et al: In vitro
sequence-dependent synergism between paclitaxel and gefitinib in
human lung cancer cell lines. Cancer Chemother Pharmacol.
67:637–646. 2011. View Article : Google Scholar
|
|
30
|
Tsai CM, Chen JT, Stewart DJ, et al:
Antagonism between gefitinib and cisplatin in non-small cell lung
cancer cells: why randomized trials failed? J Thorac Oncol.
6:559–568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gandara D, Narayan S, Lara PN Jr, et al:
Integration of novel therapeutics into combined modality therapy of
locally advanced non-small cell lung cancer. Clin Cancer Res.
11:5057s–5062s. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gumerlock PH, Pryde BJ, Kimura T, et al:
Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small
cell lung carcinoma (NSCLC). J Clin Oncol. 22:26612003.
|
|
34
|
Mahaffey CM, Davies AM, Lara PN Jr, et al:
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung
cancer cell lines treated with docetaxel and erlotinib: rationale
for pharmacodynamic separation. Clin Lung Cancer. 8:548–553. 2007.
View Article : Google Scholar
|
|
35
|
Stewart DJ, Raaphorst GP, Yau J and
Beaubien AR: Active vs. passive resistance, dose-response
relationships, high dose chemotherapy, and resistance modulation: a
hypothesis. Invest New Drugs. 14:115–130. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stewart DJ: Mechanisms of resistance to
cisplatin and carboplatin. Crit Rev Oncol Hematol. 63:12–31. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hall MD, Okabe M, Shen DW, Liang XJ and
Gottesman MM: The role of cellular accumulation in determining
sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol
Toxicol. 48:495–535. 2008. View Article : Google Scholar
|
|
38
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Citri A and Yarden Y: EGF-ERBB signalling:
towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. New Engl J Med. 358:1160–1174.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Van Schaeybroeck S, Kyula J, Kelly DM, et
al: Chemotherapy-induced epidermal growth factor receptor
activation determines response to combined gefitinib/chemotherapy
treatment in non-small cell lung cancer cells. Mol Cancer Ther.
5:1154–1165. 2006. View Article : Google Scholar : PubMed/NCBI
|
